243 related articles for article (PubMed ID: 7929312)
1. The inhibitory effect of factor J on the alternative complement pathway.
González-Rubio C; Jiménez-Clavero MA; Fontán G; López-Trascasa M
J Biol Chem; 1994 Oct; 269(42):26017-24. PubMed ID: 7929312
[TBL] [Abstract][Full Text] [Related]
2. Eosinophil granule major basic protein regulates generation of classical and alternative-amplification pathway C3 convertases in vitro.
Weiler JM; Gleich GJ
J Immunol; 1988 Mar; 140(5):1605-10. PubMed ID: 3346544
[TBL] [Abstract][Full Text] [Related]
3. Factor J, an inhibitor of the classical and alternative complement pathway, does not inhibit esterolysis by factor D.
González-Rubio C; González-Muñiz R; Jiménez-Clavero MA; Fontán G; López-Trascasa M
Biochim Biophys Acta; 1996 Jul; 1295(2):174-8. PubMed ID: 8695643
[TBL] [Abstract][Full Text] [Related]
4. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the alternative C3 convertase and classical C5 convertase of complement by group A streptococcal M protein.
Hong K; Kinoshita T; Takeda J; Kozono H; Pramoonjago P; Kim YU; Inoue K
Infect Immun; 1990 Aug; 58(8):2535-41. PubMed ID: 2142480
[TBL] [Abstract][Full Text] [Related]
6. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
Waldo FB; Forristal J; Beischel L; West CD
J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
[TBL] [Abstract][Full Text] [Related]
7. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
8. Complement 1 inhibitor is a regulator of the alternative complement pathway.
Jiang H; Wagner E; Zhang H; Frank MM
J Exp Med; 2001 Dec; 194(11):1609-16. PubMed ID: 11733575
[TBL] [Abstract][Full Text] [Related]
9. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
Fishelson Z; Müller-Eberhard HJ
J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
[TBL] [Abstract][Full Text] [Related]
10. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase.
Gigli I; Sorvillo J; Mecarelli-Halbwachs L; Leibowitch J
J Exp Med; 1981 Jul; 154(1):1-12. PubMed ID: 7019379
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
Fearon DT
Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
[TBL] [Abstract][Full Text] [Related]
13. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
Sahu A; Isaacs SN; Soulika AM; Lambris JD
J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
[TBL] [Abstract][Full Text] [Related]
14. Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme.
Halbwachs L; Leveillé M; Lesavre P; Wattel S; Leibowitch J
J Clin Invest; 1980 Jun; 65(6):1249-56. PubMed ID: 6902727
[TBL] [Abstract][Full Text] [Related]
15. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
Fearon DT; Austen KF
J Exp Med; 1977 Jul; 146(1):22-33. PubMed ID: 559720
[TBL] [Abstract][Full Text] [Related]
16. Activation of the classical complement pathway by nephritic factor bound to the alternative pathway C3/C5 convertase.
Sobel AT; Cooper NR; Schreiber RD
J Immunol; 1979 Jan; 122(1):34-8. PubMed ID: 762421
[TBL] [Abstract][Full Text] [Related]
17. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
Kozlov LV; Shibanova ED; Zinchenko AA
Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
Gigli I; Fujita T; Nussenzweig V
Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6596-600. PubMed ID: 293746
[TBL] [Abstract][Full Text] [Related]
19. Cell-surface regulation of the human alternative pathway of complement. Sheep but not rabbit erythrocytes express factor I-dependent cofactor activity.
Ezzell JL; Parker CJ
Scand J Immunol; 1992 Jul; 36(1):79-87. PubMed ID: 1535452
[TBL] [Abstract][Full Text] [Related]
20. Oxiagin from the Naja oxiana cobra venom is the first reprolysin inhibiting the classical pathway of complement.
Shoibonov BB; Osipov AV; Kryukova EV; Zinchenko AA; Lakhtin VM; Tsetlin VI; Utkin YN
Mol Immunol; 2005 Jun; 42(10):1141-53. PubMed ID: 15829304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
